Delivery of plant-made vaccines and therapeutics

Biotechnology Advances

Volumn 30, Issue 2, 2012, Pages 440-448

  Pelosi, Assunta ^a   Shepherd, Robert ^a   Walmsley, Amanda M ^a  

^a MONASH UNIVERSITY   (Australia)

Author keywords

Mucosal immunology; Oral delivery; Parenteral delivery; Plant made proteins

Indexed keywords

BIOPHARMACEUTICALS; CARRIER VEHICLES; FURTHER DEVELOPMENT; GLOBAL SOLUTIONS; IMMUNE SYSTEMS; IMMUNOGENICITY; ORAL DELIVERY; PARENTERAL DELIVERY; PHARMACEUTICAL DELIVERY; PLANT-MADE PHARMACEUTICALS;

BIOTECHNOLOGY;

IMMUNOLOGY;

IMMUNOLOGICAL ADJUVANT; VACCINE;

DRUG; IMMUNE SYSTEM; IMMUNOASSAY; PROTEIN; VACCINE;

ANIMAL; ANIMAL MODEL; BIOSYNTHESIS; CLINICAL TRIAL (TOPIC); DRUG DELIVERY SYSTEM; GENETICS; HUMAN; METABOLISM; METHODOLOGY; MUCOSAL IMMUNITY; ORAL DRUG ADMINISTRATION; REVIEW; TRANSGENIC PLANT; VACCINATION;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, ORAL; ANIMALS; CLINICAL TRIALS AS TOPIC; DRUG DELIVERY SYSTEMS; HUMANS; IMMUNITY, MUCOSAL; MODELS, ANIMAL; PLANTS, GENETICALLY MODIFIED; VACCINATION; VACCINES;

EID: 84856970457     PISSN: 07349750     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.biotechadv.2011.07.018     Document Type: Review

References (122)

1. Ahmad N., Sharma S., Alam M.K., Singh V.N., Shamsi S.F., Mehta B.R., et al. Rapid synthesis of silver nanoparticles using dried medicinal plant of basil. Colloids Surf B Biointerfaces 2010, 81:81-86.
2. Alvarez M., Topal E., Martin F., Cardineau G. Higher accumulation of F1-V fusion recombinant protein in plants after induction of protein body formation. Plant Mol Biol 2010, 72:75-89.
3. Bachmann M.F., Jennings G.T. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat Rev Immunol 2010, 10:787-796.
4. Baez J., Russell D., Craig J., Cass P.L. Corn seed production of therapeutic proteins moves forward. Bio Pharm 2000, 13:50-54.
5. Barta A., Sommergruber K., Thompson D., Hartmuth K., Matzke M.A., Matzke A.J.M. The expression of a nopaline synthase-human growth hormone chimaeric genes in transformed tobacco and sunflower callus tissue. Plant Mol Biol 1986, 6:347-357.
6. Boothe J., Nykiforuk C., Shen Y., Zaplachinski S., Szarka S., Kuhlman P., et al. Seed-based expression systems for plant molecular farming. Plant Biotechnol J 2010, 8:588-606.
7. Boothe J.G., Nykiforuk C.L., Kuhlman P.A., Whelan H., Pollock W.B.R., Clark S., et al. Analytical characterization, safety and clinical bioequivalence of recombinant human insulin from transgenic plants. American Diabetes Association's 69th Scientific Sessions 2009.
8. Bos J.D., Kapsenberg M.L. The skin immune system: progress in cutaneous biology. Immunol Today 1993, :75-78.
9. Chandran S.P., Chaudhary M., Pasricha R., Ahmad A., Sastry M. Synthesis of gold nanoparticles and silver nanoparticles using Aloe vera plant extract. Biotechnol Prog 2006, 22:577-583.
10. Chargelegue D., Drake P.M.W., Obregon P., Prada A., Fairweather N., Ma J.K.-C. Highly immunogenic and protective recombinant vaccine candidate expressed in transgenic plants. Infect Immun 2005, 73:5915-5922.
11. Chen H., Torchilin V., Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res 1996, 13:1378-1383.
12. Chen Y.-S., Hung Y.-C., Lin W.-H., Huang G.S. Assessment of gold nanoparticles as a size-dependent vaccine carrier for enhancing the antibody response against synthetic foot-and-mouth disease virus peptide. Nanotechnology 2010, 21:195101. 10.1088/0957-4484/21/19/195101.
13. Chikwamba R., Cunnick J., Hathaway D., McMurray J., Mason H., Wang K. A functional antigen in a practical crop: LT-B producing maize protects mice against Escherichia coli heat labile enterotoxin (LT) and cholera toxin (CT). Transgenic Res 2002, 11:479-493.
14. Ching C., Black R., Helliwell T., Savage A., Barr H., Rhodes J. Use of lectin histochemistry in pancreatic cancer. J Clin Pathol 1988, 41:324-328.
15. Chyu K.-Y., Yano J., Li X., Zhou J., Lio W.M., Chan C., et al. Safflower seed-derived Des-1,2-apoA1milano reduces atherosclerosis in hypercholesterolemic apolipoprotein E (-/-) mice. J Am Coll Cardiol 2010, 55:A50.
16. Corr S., Gahan C., Hill C. M-cells: origin, morphology and role in mucosal immunity and microbial pathogenesis. FEMS Immunol Med Microbiol 2008, 52:2-12.
17. Cox J., Sjölander A., Barr I. ISCOMs and other saponin based adjuvants. Adv Drug Deliv Rev 1998, 32:247-271.
18. Curtiss R., Cardineau G.A. Oral immunization by transgenic plants. World Intellectual Property Organization: PCT/US89/03799 1990.
19. Czerkinsky C., Holmgren J. Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues. Curr Top Microbiol Immunol 2012, 354:1-18.
20. D'Aoust M.-A., Couture M.M.-J., Charland N., Trepanier S., Landry N., Ors F., et al. The production of hemagglutinin-based virus-like particles in plants: a rapid, efficient and safe response to pandemic influenza. Plant Biotechnol J 2010, 8:607-619.
21. De Jaeger G., Scheffer S., Jacobs A., Zambre M., Zobell O., Goossens A., et al. Boosting heterologous protein production in transgenic dicotyledonous seeds using Phaseolus vulgaris regulatory sequences. Nat Biotechnol 2002, 12:1265-1268.
22. Di Sansebastiano G.-P., Paris N., Marc-Martin S., Neuhaus J.M. Specific accumulation of GFP in a non-acidic vacuolar compartment via a C-terminal propeptide-mediated sorting pathway. Plant J 1998, 15.
23. Doel T. FMD vaccines. Virus Res 2003, 91:81-99.
24. Drake P.M.W., Thangaraj H. Molecular farming, patents and access to medicines. Expert Rev Vaccines 2010, 9:811-819.
25. Dukes C., Bussey H.J.R. The number of lymphoid follicles of the human large intestine. J Pathol 1926, 29:111-116.
26. Elson C., Ealding W. Cholera toxin feeding did not induce oral tolerance in mice and abrogated oral tolerance to an unrelated protein antigen. J Immunol 1984, 133:2892-2897.
27. EMEA Guideline on the quality of biological active substances produced by stable transgene expression in higher plants. Doc. Ref. EMEA/CHMP/BWP/48316/2006 2008 Retrieved 12 Jul 2011. http://www.ema.europa.eu.
28. Faria A., Weiner H. Oral tolerance. Immunol Rev 2005, 206:232-259.
29. Farran I., McCarthy-Suarez I., Rio-Manterola F., Mansilla C., Lasarte J.J., Mingo-Castel A.M. The vaccine adjuvant extra domain A from fibronectin retains its proinflammatory properties when expressed in tobacco chloroplasts. Planta 2010, 231:977-990.
30. FDA Guidance for industry: drugs, biologics, and medical devices derived from bioengineered plants for use in humans and animals Retrieved 12 Jul 2011. http://www.fda.gov/downloads/AnimalVeterinary/GuidanceComplianceEnforcement/GuidanceforIndustry/UCM055424.pdf.
31. Fontaine T., Irving G. Isolation and partial characterization of crystalline tomatine, an antibiotic agent from the tomato plant. Arch Biochem 1948, 18:467-475.
32. Friedman M. Tomato glycoalkaloids: role in the plant and in the diet. J Agric Food Chem 2002, 50:5751-5780.
33. Friedman M., Fitch T., Yokoyama W. Lowering of plasma LDL cholesterol in hamsters by the tomato glycoalkaloid tomatine. Food Chem Toxicol 2000, 38:549-553.
34. Friedman M., Henika P., Mackey B. Feeding of potato, tomato and eggplant alkaloids affects food consumption and body and liver weights in mice. J Nutr 1996, 126:989-999.
35. Garinot M., Fiévez V., Pourcelle V., Stoffelbach F., des Rieux A., Plapied L., et al. PEGylated PLGA-based nanoparticles targeting M cells for oral vaccination. J Control Release 2007, 120:195-204.
36. Gee J., Wortley G., Johnson I., Price K., Rutten A., Houben G., et al. Effects of saponins and glycoalkaloids on the permeability and viability of mammalian intestinal cells and on the integrity of tissue preparations in vitro. Toxicol In Vitro 1996, 10:117-128.
37. Gizzarelli F., Corinti S., Barletta B., Iacovacci P., Brunetto B., Butteroni C., et al. Evaluation of allergenicity of genetically modified soybean protein extract in a murine model of oral allergen-specific sensitization. Clin Exp Allergy 2006, 36:238-248.
38. Gockel C., Russell M. Induction and recall of immune memory by mucosal immunization with a non-toxic recombinant enterotoxin-based chimeric protein. Immunology 2005, 116:477-486.
39. Gora-Sochacka A., Redkiewicz P., Napiorkowska B., Gaganidze D., Brodzik R., Sirko A. Recombinant mouse granulocyte-macrophage colovy-stimulating factor is glycosylated in transgenic tobacco and maintains its biological activity. J Interferon Cytokine Res 2010, 30:135-141.
40. Granell A., Fernandez-del-Carmen A., Orzaez D. In planta production of plant-derived and non-plant-derived adjuvants. Expert Rev Vaccines 2010, 9:843-858.
41. Greenwood D.L.V., Dynon K., Kalkanidis M., Xiang S., Plebanski M., Scheerlinck J.-P.Y. Vaccination against foot-and-mouth virus using peptides conjugated to nano beads. Vaccine 2008, 26:2706-2713.
42. Grossinklaus S., Rempel R., Pinkhasov J., Walmsley A.M. Application of Quillaja saponaria extracts as oral adjuvants for plant-made vaccines. Expert Opin Biol Ther 2004, 4:947-958.
43. Gullberg, Keita A., Salim S., Andersson M., Caldwell K., Söderholm J., et al. Identification of cell adhesion molecules in the human follicle-associated epithelium that improve nanoparticle uptake into the Peyer's patches. J Pharmacol Exp Ther 2006, 319:632-639.
44. Hajishengallis G., Hollingshead S., Koga T., Russell M. Mucosal immunization with a bacterial protein antigen genetically coupled to cholera toxin A2/B subunits. J Immunol 1995, 154:4322-4332.
45. Hajishengallis G., Tapping R., Martin M., Nawar H., Lyle E., Russell M., et al. Toll-like receptor 2 mediates cellular activation by the B subunits of type II heat-labile enterotoxins. Infect Immun 2005, 73:1343-1349.
46. Helgeby A., Robson N., Donachie A., Beackock-Sharp H., Lövgren K., Schön K., et al. The combined CTA1-DD/ISCOM adjuvant vector promotes priming of mucosal and systemic immunity to incorporated antigens by specific targeting of B cells. J Immunol 2006, 176:3697-3706.
47. Hood E.E., Witcher D.R., Maddock S., Meyer T., Baszcynski C., Bailey M., et al. Commercial production of avidin from transgenic maize: characterization transformant, production, processing, extraction and purification. Mol Breed 1997, 3:291-306.
48. +T helper cell phenotype development in a T cell receptor-αβ-transgenic model. J Exp Med 1995, 1579-1584.
49. Jang M., Kweon M.-N., Iwatani K., Yamamoto M., Terahara K., Sasakawa C., et al. Intestinal villous M cells: an antigen entry site in the mucosal epithelium. Proc Natl Acad Sci U S A 2004, 101:6110-6115.
50. Kapusta J., Modelska A., Figlerowicz M., Pniewski T., Letellier M., Lisowa O., et al. A plant-derived edible vaccine against hepatitis B virus. FASEB J 1999, 13:1796-1799.
51. Kelsall B. Recent progress in understanding the phenotype and function of intestinal dendritic cells and macrophages. Mucosal Immunol 2008, 1:460-469.
52. Kupper T.S., Fuhlbrigge R.C. Immune surveillance in the skin: mechanisms and clinical consequences. Nat Rev Immunol 2004, 4:211-222.
53. Landry N., Ward B.J., Trepanier S., Montomoli E., Dargis M., Lapini G., et al. Preclinical and clinical development of plant-made virus-like particle vaccine against avian H5N1 influenza. PLoS One 2010, 5:e15559. 10.1371/journal.pone.0015559.
54. Lavelle E., Grant G., Pusztai A., Pfüller U., O'Hagan D. Mucosal immunogenicity of plant lectins in mice. Immunology 2000, 99:30-37.
55. Lentz E.M., Segretin M.E., Morgenfeld M.M., Wirth S.A., Dus Santos M.J., Mozgovoj M.V., et al. High expression level of a foot and mouth disease virus epitope in tobacco transplastomic plants. Planta 2010, 231:387-395.
56. Lin J., Zhang J., Dong X., Fang H., Chen J., Su N., et al. Safety and immunogenicity of an inactivated adjuvanted whole-virion influenza A (H5N1) vaccine: a phase I randomised controlled trial. Lancet 2006, 991-997.
57. Liang S., Hajishengallis G. Heat-labile enterotoxins as adjuvants or anti-inflammatory agents. Immunol Invest 2010, 39:449-467.
58. Ling H.-Y., Pelosi A., Walmsley A.M. Current status of plant-made vaccines for veterinary purposes. Expert Rev Vaccines 2010, 971-982.
59. Limaye A., Koya V., Samsam M. Receptor-mediated oral delivery of a bioencapsulated green fluorescent protein expressed in transgenic choloroplasts into the mouse circulatory system. FASEB J 2006, 20:37-46.
60. MacPherson A., McCoy K., Johansen F.-E., Brandtzaeg P. The immune geography of IgA induction and function. Mucosal Immunol 2008, 1:11-22.
61. Manocha M., Pal P., Chitralekha K., Thomas B., Tripathi V., Gupta S., et al. Enhanced mucosal and systemic immune response with intranasal immunization of mice with HIV peptides entrapped in PLG microparticles in combination with Ulex Europaeus-I lectin as M cell target. Vaccine 2005, 23:5599-5617.
62. Manolova V., Flace A., Bauer M., Schwarz K., Saudan P., Bachmann M.F. Nanoparticles target distinct dendritic cell populations according to their size. Eur J Immunol 2008, 38:1404-1413.
63. Marillonnet S., Giritch A., Gils M., Kandzia R., Klimyuk V., Gleba Y. In planta engineering of viral RNA replicons: efficient assembly by recombination of DNA modules delivered by Agrobacterium. Proc Natl Acad Sci U S A 2004, 101:6852-6857.
64. Martin B., Suckow M., Wolter W., Berger T., Turner J. Use of mucosal immunization with porcine zona pellucida (PZP) in mice and rabbits. Anim Reprod Sci 2006, 93:372-378.
65. Mason H., Warzecha H., Mor T., Arntzen C. Edible plant vaccines: applications for prophylactic and therapeutic molecular medicine. Trends Mol Med 2002, 8:324-329.
66. Mason H.S., Ball J.M., Shi J.-J., Jlang X., Estes M.K., Arntzen C.J. Expression of Norwalk virus capsid protein in transgenic tobacco and potato and its oral immunogenicity in mice. Proc Natl Acad Sci USA 1996, 93:5335-5340.
67. Mason H.S., Haq T.A., Clements J.D., Arntzen C.J. Edible vaccine protects mice against Escherichia coli heat-labile enterotoxin (LT): potatoes expressing a synthetic LT-B gene. Vaccine 1998, 16:1336-1343.
68. Mason H.S., Lam D.M.K., Arntzen C.J. Expression of hepatitis B surface antigen in transgenic plants. Proc Natl Acad Sci U S A 1992, 89:11745-11749.
69. McCormick A.A., Reddy S., Reinl S.J., Cameron T.I., Czerwinkski D.K., Vojdani F., et al. Plant-produced idiotype vaccines for the treatment of non-Hodgkin's lymphoma: safety and immunogenicity in a Phase I clinical study. Proc Natl Acad Sci U S A 2008, 105:10131-10136.
70. McCormick A.A., Reinl S.J., Cameron T.I., Vojdani F., Fronefield M., Levy R., et al. Individualized human scFv vaccines produced in plats: humoral anti-idiotype responses in vaccinated mice confirm relevance to the tumor Ig. J Immunol Methods 2003, 278:95-104.
71. Medicago Medicago reports positive phase II final results for its avian flu pandemic vaccine Retrieved 12 Jul 2011. http://www.medicago.com/English/news/News-Releases/News-ReleaseDetails/2011/Medicago-reports-positive-Phase-II-final-results-for-its-avian-flu-pandemic-vaccine1125833/default.aspx.
72. Medina-Bolivar F., Wright R., Funk V., Sentz D., Barroso L., Wilkins T.D., et al. A non-toxic lectin for antigen delivery of plant-based mucosal vaccines. Vaccine 2003, 21:997-1005.
73. Ménard S., Cerf-Bensussan N., Heyman N.M. Multiple facets of intestinal permeability and epithelial handling of dietary antigens. Mucosal Immunol 2010, 3:247-259.
74. Merdano G., Dolan M.C., Stephens N.T., McMickle A., Erf G., Radin D., et al. Efficient plant-based production of chicken interleukin-12 yields a strong immunostimulatory cytokine. J Interferon Cytokine Res 2010, 30:143-153.
75. Mohanan D., Slutter B., Henriksen-Lacey M., Jiskoot W., Bouwstra J.A., Perrie Y., et al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particluate antigen-delivery systems. J Control Release 2010, 147:342-349.
76. Moingeon P., Haensler J., Lindberg A. Towards the rational design of Th1 adjuvants. Vaccine 2001, 19:4363-4372.
77. Morrow W., Yang Y.-W., Sheikh N. Immunobiology of the tomatine adjuvant. Vaccine 2004, 22:2380-2384.
78. Mowat A., Maloy K., Donachie A. Immune-stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 1993, 80:527-534.
79. Neutra M., Kozlowski P. Mucosal vaccines: the promise and the challenge. Nat Rev Immunol 2006, 6:148-158.
80. Neutra M., Mantis N., Kraehenbuhl J. Collaboration of epithelial cells with organized mucosal lymphoid tissues. Nat Immunol 2001, 2:1004-1009.
81. Newman K.D., Elamanchili P., Kwon G.S., Samuel J. Uptake of poly(d, l-lactic-co-glycolic acid) microspheres by antigen-presenting cells in vivo. J Biomed Mater Res 2002, 60:480-486.
82. Nykiforuk C.L., Boothe J.G., Murray E.W., Keon R.G., Goren H.J., Markley N.A., et al. Transgenic expression and recovery of biologically active recombinant human insulin from Arabidopsis thaliana seeds. Plant Biotechnol J 2006, 4:77-85.
83. Nykiforuk C.L., Shen Y.S., Mauuray E.W., Boothe J.G., Busseuil D., Rheaume E., et al. Expression and recovery of biologically active recombinant apolipoprotein AIMilano from transgenic safflower (Carthamus tinctorius) seeds. Plant Biotechnol J 2011, 9:250-263.
84. Oakes J., Piller K., Bost K. An antibody response to cholera toxin, but not soy proteins, following oral administration of adjuvanted soybean formulations. Food Agric Immunol 2009, 20:305-317.
85. Owen R., Jones A. Epithelial cell specialization within human Peyer's patches: an ultrastructural study of intestinal lymphoid follicles. Gastroenterology 1974, 66:189-203.
86. Oyewumi M.O., Kumar A., Cui Z. Nano-microparticles as immune adjuvants: correlating particle sizes and resultant immune responses. Expert Rev Vaccines 2010, 9:1095-1107.
87. Paciotti G.F., Myer L., Weinreich D., Goia D., Pavel N., McLaughlin R.E., et al. Colloidal gold: a novel nanoparticle vector for tumor directed drug delivery. Drug Deliv 2004, 11:169-183.
88. Peek L.J., Middaugh C.R., Berkland C. Nanotechnology in vaccine delivery. Adv Drug Deliv Rev 2008, 60:915-928.
89. Pelosi A, Shepherd R, De Guzman, G, Hamill J, Meeusen, E, Sanson G, et al. in press. The release and induced immune responses of a plant-made and delivered antigen in the mouse gut. Curr Drug Deliv.
90. Penney C., Thomas D.R., Deen S.A., Walmsley A.M. Plant-made vaccines in support of the Millennium Development Goals. Plant Cell Rep 2011, 30:789-798.
91. Pickering R., Smith S., Strugnell R., Wesselingh S., Webster D. Crude saponins improve the immune response to an oral plant-made measles vaccine. Vaccine 2006, 24:144-150.
92. Querec T., Akondy R., Lee E., Cao W., Nakaya H., Teuwen D., et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat Immunol 2009, 10:116-125.
93. Rescigno M., Urbano M., Valzasina B., Francoloni M., Rotta G., Bonasio R., et al. Dendritic cells express tight junction proteins and penetrate gut epithelial monolayers to sample bacteria. Nat Immunol 2001, 2:361-367.
94. Reuter F., Bade S., Hirst T.R., Frey A. Bystander protein protects potential vaccine-targeting ligands against intestinal proteolysis. J Control Release 2009, 137:98-103.
95. Richman L.K., Chiller J.M., Brown W.R., Hanson D.G., Vaz N.M. Enterically induced immunologic tolerance: I. Induction of suppressor T lymphocytes by intragastric administration of soluble proteins. J Immunol 1978, 121:2429-2434.
96. Ruhlman T., Ahangari R., Devine A., Samsam M., Daniell H. Expression of cholera toxin B-proinsulin fusion protein in lettuce and tobacco chloroplasts-oral administration protects against development of insulitis in non-obese diabetic mice. Plant Biotechnol J 2007, 5:495-510.
97. Rybicki E. Plant-produced vaccines: promise and reality. Drug Discov Today 2009, 14:16-24.
98. Sakaguchi S., Fukuma K., Kuribayashi K., Masuda T. Organ-specific autoimmune diseases induced in mice by elimination of T cell subset. I. Evidence for the active participation of T cells in natural self-tolerance; deficit of a T cell subset as a possible cause of autoimmune disease. J Exp Med 1985, 161:72-87.
99. Sjölander A., Cox J. Uptake and adjuvant activity of orally delivered saponin and ISCOM vaccines. Adv Drug Deliv Rev 1998, 34:321-338.
100. Smits H., Gloudemans A., van Nimwegen M., Willart M., Soullié T., Muskens F., et al. Cholera toxin B suppresses allergic inflammation through induction of secretory IgA. Mucosal Immunol 2009, 2:331-339.
101. Sparg S., Light M., van Staden J. Biological activities and distribution of plant saponins. J Ethnopharmacol 2004, 94:219-243.
102. Starnes D.L., Jain A., Sahi S.V. In planta engineering of gold nanoparticles of desirable geometries by modulating growth conditions: an environment-friendly approach. Environ Sci Tehnol 2010, 44:7110-7115.
103. Streatfield S. Mucosal immunization using recombinant plant-based oral vaccines. Methods 2006, 38:150-157.
104. Streatfield S.J., Howard J.A. Plant-based vaccines. Int J Parasitol 2003, 479-493.
105. Sullivan S.P., Koutsonanos D.G., del Pilar Martin M., Lee J.W., Zarnitsyn V., Choi S.-O., et al. Dissolving polymer microneedle patches for influenza vaccination. Nat Med 2010, 16:915-921.
106. Sun H.-X., Xie Y., Ye Y.-P. Advances in saponin-based adjuvants. Vaccine 2009, 27:1787-1796.
107. Sun J., Holmgren J., Czerkinsky C. Cholera toxin B subunit: an efficient transmucosal carrier-delivery system for induction of peripheral immunological tolerance. Proc Natl Acad Sci USA 1994, 91:10795-10799.
108. Tacket C.O., Mason H.S., Losonsky G., Clements J.D., Levine M.M., Arntzen C.J. Immunogenicity in humans of a recombinant bacterial antigen delivered in a transgenic potato. Nat Med 1998, 4:607-609.
109. Tacket C.O., Mason H.S., Losonsky G., Estes M.K., Levine M.M., Arntzen C.J. Human immune responses to a novel Norwalk virus vaccine delivery in transgenic potatoes. J Infect Dis 2000, 182:302-305.
110. Tacket C.O., Pasetti M.F., Edelman R., Howard J.A., Streatfield S. Immunogenicity of recombinant LT-B delivered orally to humans in transgenic corn. Vaccine 2004, 22:4385-4389.
111. Thanavala Y., Mahoney M., Pal S., Scott A., Richter L., Natarajan N., et al. Immunogenicity in humans of an edible vaccine for hepatitis B. Proc Natl Acad Sci U S A 2005, 102:3378-3382.
112. Verma D., Moghimi B., LoDuca P., Singh H., Hoffman B., Herzog R., et al. Oral delivery of bioencapsulated coagulation factor IX prevents inhibitor formation and fatal anaphylaxis in hemophilia B mice. Proc Natl Acad Sci U S A 2010, 107:7101-7106.
113. Vermij P. USDA approves the first plant-based vaccine. Nat Biotechnol 2006, 24:234.
114. Vitale V., Pedrazzini E. Recombinant pharmaceuticals from plants: the plant endomembrane system as bioreactor. Mol Interv 2005, 5:216-225.
115. Warzecha H., Mason H.S., Lane C., Tryggvesson A., Rybicki E., Williamson A.-L., et al. Oral immunogenicity of human papillomavirus-like particles expressed in potato. J Virol 2003, 77:8702-8711.
116. Woodard S.L., Mayor J.M., Bailey M.R., Barker D.K., Love R.T., Lane J.R., et al. Maize (Zea mays)-derived bovine trypsin: characterization of the first large-scale, commercial protein product from transgenic plants. Biotechnol Appl Biochem 2003, 38:123-130.
117. Wu J., Liu S.-Z., Dong S.-S., Dong X.-P., Zhang W.-L., Lu M., et al. Safety and immunogenicity of adjuvanted inactivated split-virion and whole-virion influenza A (H5N1) vaccines in children: a phase I-II randomized trial. Vaccine 2010, 28:6221-6227.
118. Xiang S.D., Scholzen A., Minigo G., David C., Apostolopoulos V., Mottram P.L., et al. Pathogen recognition and development of particulate vaccines: does size matter?. Methods 2006, 40:1-9.
119. Yamanaka T., Vincken J.-P., de Waard P., Sanders M., Takada N., Gruppen H. Isolation, characterization, and surfactant properties of the major triterpenoid glycosides from unripe tomato fruits. J Agric Food Chem 2008, 56:11432-11440.
120. Yang Y.-W., Sheikh N., Morrow W. The ultrastructure of tomatine adjuvant. Biomaterials 2002, 23:4677-4686.
121. Yusibov V., Hooper D.C., Spitsin S.V., Fleysh N., Kean R.B., Mikheeva T., et al. Expression in plants and immunogenicity of plant virus-based experimental rabies vaccine. Vaccine 2002, 2002:3155-3164.
122. Zhong G.-Y., Peterson D., Delaney D.E., Bailey M., Witcher D.R., Register J.C., et al. Commercial production of aprotinin in transgenic maize seeds. Mol Breed 1999, 5:345-356.